Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
How does the PlexusDx Precision Peptide Genetic Test help with contraceptive planning
282.63 Ships from Netherlands, VAT incl
An oncolytic virus delivering tumor-irrelevant bystander T-cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Yes, this combination is common
US$ 25.23
US$ 28.30
US$ 22.10
US$ 28.85
US$ 29.58
